Serum titres of anti-glutamic acid decarboxylase-65 and anti-IA-2 autoantibodies are associated with different immunoregulatory milieu in newly diagnosed type 1 diabetes patients

Clinical and Experimental Immunology

Volumn 168, Issue 1, 2012, Pages 60-67

  Andrade Lima Gabbay, M ^a   Sato, M N ^b   Duarte, A J S ^b   Dib, S A ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Cytokine; Pancreatic autoantibodies; Regulatory T cells; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; C PEPTIDE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HEMOGLOBIN A1C; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; INSULINOMA ASSOCIATED ANTIGEN 2 AUTOANTIBODY; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIBODY TITER; ARTICLE; BODY MASS; CD4+ CD25+ T LYMPHOCYTE; CELL DAMAGE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HUMAN; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ADOLESCENT; AUTOANTIBODIES; CHEMOKINES; CHILD; CYTOKINES; DIABETES MELLITUS, TYPE 1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTAMATE DECARBOXYLASE; HLA-DR3 ANTIGEN; HLA-DR4 ANTIGEN; HUMANS; INSULIN-SECRETING CELLS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22;

EID: 84857700615     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04538.x     Document Type: Article

References (44)

1. Zhang L, Eisenbarth GS. Prediction and prevention of Type 1 diabetes mellitus. J. Diabetes 2001; 3:48-57.
2. Moghaddam PF, Schloot NC, Kappler S, Seibler J, Kolb H. An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes 2003; 52:1137-42.
3. Sabbah E, Savola K, Kulmala P etal. for The Childhood Diabetes in Finland Study Group. Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. J Clin Endocrinol Metab 1999; 84:1534-39.
4. Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet β-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998; 55:1139-49.
5. Wenzlau JM, Frisch LM, Gardner TJ, Sarkar S, Hutton JC, Davidson HW. Novel antigens in type 1 diabetes: the importance of ZNT8. Curr Diab Rep 2009; 9:105-12.
6. Harrison LC, Honeyman MC, DeAizpurua HJ etal. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet 1993; 341:1365-69.
7. Awdeh ZL, Yunis EJ, Audeh MJ etal. A genetic explanation for the rising incidence of type 1 diabetes, a polygenic disease. J Autoimmun 2006; 27:174-81.
8. Muller-Hilke B, Mitchison NA. The role of HLA promoters in autoimmunity. Curr Pharm Des 2006; 12:3743-52.
9. Bottini N, Vang T, Cucca F, Mustelin T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol 2006; 18:207-13.
10. Hermann R, Lipponen K, Kiviniemi M etal. Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin autoimmunity and progression to type 1 diabetes. Diabetologia 2006; 49:1198-208.
11. Petrone A, Spoletini M, Zampetti S etal. The PTPN22 1858T gene variant in type 1 diabetes is associated with reduced residual β-cell function and worse metabolic control. Diabetes Care 2008; 31:1214-18.
12. Schloot NC, Hanifi-Moghaddam P, Aabenhus-Andersen N etal. Association of immune mediators at diagnosis of Type 1 diabetes with later clinical remission. Diabet Med 2007; 24:512-20.
13. Erbagci AB, Tarakçioglu M, Coskun Y, Sivasli E, Namiduru ES. Mediators of inflammation in children with type 1 diabetes mellitus: cytokines in type 1 diabetic children. Clin Biochem 2001; 34:645-50.
14. Cavallo MG, Pozzilli P, Bird C etal. Cytokines in sera from insulin-dependent diabetic patients at diagnosis. Clin Exp Immunol 1991; 86:256-59.
15. Ryden A, Stechova K, Durilova M, Faresjo M. Switch from a dominant Th1-associated immune profile during the pre-diabetic phase in favour of a temporary increase of a Th3-associated and inflammatory immune profile at the onset of type 1 diabetes. Diabetes Metab Res Rev 2009; 25:335-49.
16. Mallone R, Brezar V. To B or not to B (Anti)bodies of evidence on the crime scene of Type 1 diabetes? Diabetes 2011; 60:2020-22.
17. Kunz M, Ibrahim SM. Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm 2009; 2009:979258.
18. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004; 114:589-97.
19. Almawi WY, Tamin H, Azar ST. T helper type 1 and 2 cytokines mediate the onset and progression of type 1 (insulin-dependent) diabetes. J Clin Endocrinol Metab 1999; 84:149-502.
20. Rapoport MJ, Mor A, Vardi P etal. Decreased secretion of Th2 cytokines precedes up-regulation and delayed secretion of Th1 cytokines in activated peripheral blood mononuclear cells from patients with insulin-dependent diabetes mellitus. J Autoimmun 1998; 11:635-42.
21. Eisenbarth GS, Jeffrey J. The natural history of Type 1A diabetes. Arq Bras Endocrinol Metabol 2008; 52:146-55.
22. Borg H, Gottsater A, Landin-Olsson M, Fernlund P, Sundkvist G. High levels of antigen-specific islet antibodies predicts future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 2001; 86:3032-38.
23. Marner B, Agner T, Binder C etal. Increased reduction in fasting C-peptide is associated with islet cell antibodies in type 1 (insulin-dependent) diabetic patients. Diabetologia 1985; 28:875-80.
24. Orban T, Sosenko JM, Cuthbertson D etal. for the Diabetes Prevention Trial-Type 1 Study Group. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009; 32:2269-74.
25. Vehik K, Cuthbertson D, Ruhlig H, Schatz DA, Peakman M, Krischer JP for the DPT-1 and TrialNet Study Groups. Long-term outcome of individuals treated with oral insulin: Diabetes Prevention Trial-Type 1(DPT-1) oral insulin trial. Diabetes Care 2011; 34:1585-90.
26. Achenbach P, Warncke K, Reiter J etal. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004; 53:384-92.
27. Barker JM, Barriga KJ, Yu L etal. Prediction of autoantibody positivity and progression to type 1 diabetes: diabetes autoimmunity study in the young (DAISY). J Clin Endocrinol Metab 2004; 89:3896-902.
28. Bosi E, Braghi S, Maffi P etal. Autoantibody response to islet transplantation in type 1 diabetes. Diabetes 2001; 50:2464-71.
29. Christie MR, Molvig J, Hawkes CJ, Carstensen B, Mandrup-Poulsen T. The Canadian-European Randomized Control Trial Group. IA-2 antibody-negative status predicts remission and recovery of C-peptide levels in type 1 diabetic patients treated with cyclosporin. Diabetes Care 2002; 7:1192-97.
30. Makinen A, Harkonen T, Ilonen J, Knip M, the Finnish Pediatric Diabetes Register. Characterization of the humoral immune response to islet antigen 2 in children with newly diagnosed type 1 diabetes. Eur J Endocrinol 2008; 159:19-26.
31. Yu L, Mahon J, Boulware D etal. Zinc transporter-8 autoantibodies (ZnT8A) increase type 1 diabetes (T1D) risk in single autoantibody positive relatives. Diabetes 2011; 60:A61.
32. Moore KW, de Wall Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765.
33. Karges B, Durinovic-Bello I, Heinze E, Boehm BO, Klaus-Michael D, Karges W. Complete long-term recovery of β-cell function in autoimmune type 1 diabetes after insulin treatment. Diabetes Care 2004; 27:1207-8.
34. Straczkowski M, Kowalska I, Nikolauk A, Jrukowska A, Gorska M. Plasma interleukin-10 concentration is positively related to insulin sensitivity in young healthy individuals. Diabetes Care 2005; 28:2036-37.
35. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005; 54:92-9.
36. Achenbach P, Bonifacio E, Koczwara K, Ziegler A. Natural history of type 1 diabetes. Diabetes 2005; 54:S25-26.
37. Uno S, Imagawa A, Saisho K etal. Expression of chemokines, CXC chemokine ligand 10 (CXCL10) and CXCR3 in the inflamed islet of patients with recent-onset autoimmune type 1 diabetes. Endocr J 2010; 57:991-96.
38. Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocr Rev 2007; 28:492-520.
39. Karlsoon MGE, Sederholm Lawesson S, Ludvigsson J. Th1-like dominance in high-risk first-degree relatives of type 1 diabetic patients. Diabetologia 2000; 43:742-49.
40. Marziarz M, Janer M, Roach JC etal. The association between the PTPN22 1858C>T variant and type 1 diabetes depends on HLA risk and GAD65 autoantibodies. Genes Immun 2010; 11:406-15.
41. Volpini WMG, Testa GV, Marques SBD etal. Family-based association of HLA class II alleles and haplotypes with type 1 diabetes in Brazilians reveals some characteristics of a highly diversified population. Hum Immunol 2001; 62:1226-33.
42. Rojas-Villarraga A, Botello-Corzo D, Anaya JM. HLA-Class II in Latin American patients with type 1 diabetes. Autoimmun Rev 2010; 9:666-73.
43. Zheng W, She JX. Genetic association between a lymphoid tyrosine phosphatase (PTPN22) and type 1 diabetes. Diabetes 2005; 54:906-8.
44. Howson JMM, Stevens H, Smyth DJ etal. Evidence that HLA class I and II associations with type 1 diabetes, autoantibodies to GAD and autoantibodies to IA-2, are distinct. Diabetes 2011; 60:2635-44.